#61 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
# Clinical Relevance
Australian and New Zealand clinicians need to understand the TGA’s regulatory perspective and emerging evidence on cannabis prescribing to ensure their patients receive safe, evidence-based treatment and to maintain compliance with evolving guidelines. Direct engagement between regulators and prescribers at this conference helps identify gaps between current clinical practice and regulatory requirements, ultimately improving patient safety and treatment outcomes. As cannabis medicines remain relatively new to conventional medical practice in these countries, clinician access to TGA guidance and peer learning from experienced prescribers is essential for appropriate patient selection and dosing.
The Australian Therapeutic Goods Administration (TGA) will participate in the Australasian and New Zealand College of Cannabis Prescribers (ANZCCP) annual conference, signaling increased regulatory engagement with the emerging medical cannabis prescribing community. This collaboration reflects a critical juncture for cannabis medicine in the region, as the industry navigates regulatory challenges and evolving clinical standards. The conference will provide an opportunity for prescribers to access updated guidance directly from TGA officials while sharing clinical evidence and best practices for patient care. By facilitating dialogue between regulators and clinicians, the event aims to strengthen the evidence base for cannabis prescribing and address quality and safety concerns that have surrounded the nascent industry. Clinicians attending will gain clarity on regulatory expectations and access to the latest clinical research to inform their prescribing decisions in this rapidly evolving therapeutic area. For practitioners considering or currently prescribing cannabis products, engagement with regulatory bodies through such forums helps ensure alignment between clinical practice and evolving standards for patient safety and efficacy.
“When regulatory bodies and clinicians sit down together at conferences like this, we move past the ideological debates and into the practical work of actually helping patients, which is where the evidence lives.”
? The increasing engagement of regulatory bodies like Australia’s TGA with clinical cannabis prescriber organizations reflects growing recognition that medicinal cannabis requires structured clinical frameworks, though healthcare providers should note that evidence quality remains heterogeneous across indications and formulations. These professional forums provide valuable opportunities to align prescribing practices with emerging safety and efficacy data, yet clinicians must remain cautious about potential industry influence and remember that regulatory presence does not necessarily equate to robust clinical evidence for most cannabis-based treatments. The conference setting may help standardize approaches to patient selection, dosing, and monitoring, which is particularly important given the current patchwork of clinical guidance. Practically speaking, providers should view such professional gatherings as opportunities to stay informed about regulatory expectations and best practices, while maintaining a critical stance toward individual product claims and continuing to base prescribing decisions on the strongest available evidence and individualized patient assessment rather than consensus from conferences alone.
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
